An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine
- Registration Number
- NCT01686581
- Lead Sponsor
- Allergan
- Brief Summary
This is an observational study to describe the long term use of Onabotulinumtoxin A (BOTOX®) as prescribed by the physician for headache prophylaxis in adults with chronic migraine. All treatment decisions lie with the physician.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 641
- Prescribed BOTOX® for the prophylaxis of headaches.
- Received treatment with any botulinum toxin Type A serotype in the last 26 weeks
- Current participation in Allergan's Botox Chronic Migraine Post-Authorisation Safety Study (protocol 191622-110).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description BOTOX® botulinum toxin Type A BOTOX® (botulinum toxin Type A) administered according to physician prescription for the treatment of chronic migraine; all treatment decisions lie with the physician.
- Primary Outcome Measures
Name Time Method Mean Number of Days of Headache-related Hospital Admissions Baseline (previous 3 months prior to first dose of BOTOX@) to FU last [median 21.20 months] The number of admission days is presented as the mean, normalized to a period of 90 days. The Baseline value included admissions during the last 3 months prior to the baseline visit (first administration of BOTOX®); the Last Follow-up value included admissions since the second-to-last visit.
Percentage of Participants Admitted to the Hospital for Headache Baseline (previous 3 months prior to first dose of BOTOX®) and Last Follow-up Visit (FU last) [median 21.20 months] The Baseline value included participants who had been admitted to the hospital for headache in the last 3 months prior to the baseline visit (first administration of BOTOX®); the Last Follow-up value included participants who been admitted to the hospital for headache since the previous visit.
Percentage of Participants Who Visited Any Healthcare Professional (HCP) Baseline (previous 3 months prior to first dose of BOTOX®) to FU last [median 21.20 months] The Baseline value included participants who had visited an HCP in the last 3 months prior to the baseline visit (first administration of Botox); the value for FU last included participants who visited an HCP since the second-to-last visit.
- Secondary Outcome Measures
Name Time Method Change From Baseline in Migraine-Specific Quality of Life Questionnaire (MSQ) Score Baseline to Last Administration of BOTOX® (ADM last) [median 20.30 months] The MSQ is a 14-item questionnaire to measure health-related quality-of-life attributed to migraine in the past 4 weeks. Each item is scored on a 6-point scale where: 1=none of the time to 6=all of the time. There are 3 dimensions: Role-function Restrictive (questions 1 to 7; score range 7 to 42), Role-function Preventive (questions 8 to 11; score range 4 to 24) and Emotional-function (questions 12 to 14; score range 3 to 18). The individual dimension scores were converted to a score of 0 to 100; the total score ranged from 0 to 300 with higher numbers representing a better quality of life. A positive change from baseline in the dimension scores and the total score indicates that quality of life has improved.
Change From Baseline in the EQ-5D Questionnaire Total Score Baseline (prior to first dose of BOTOX®) to ADM last [median 20.30 months] The EQ-5D consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) assessed by the participant using a 3-point scale: 1=no problems, 2=some problems and 3=extreme problems. The combination of levels from the 5 dimensions results in a health state code. The total score is calculated by converting the health state code into a score: start with score 1.000=\[11111\] (perfect health state), subtract 0.081 (constant) for any other state, subtract nothing for level 1 on any dimension, subtract appropriate level 2 or level 3 value for each dimension from a table of constants \[Level 2: Mobility 0.069, Self-care 0.104, Usual activity 0.036, Pain/discomfort 0.123, Anxiety/depression 0.071\] \[Level 3: Mobility 0.314, Self-care 0.214, Usual activity 0.094, Pain/discomfort 0.386, Anxiety/depression 0.236\], subtract 0.269 if any dimension has a level 3 problem. Higher numbers indicate better health. A positive change from Baseline indicates improvement.
Change From Baseline in the Health State Score of the EQ-5D Questionnaire Baseline (prior to first dose of BOTOX®) to ADM last [median 20.30 months] The EQ-5D health state scale is a visual analog scale that ranges from 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating a better state of health. Participants were asked to rate their health state on a drawn line that started at 0 and ended at 100. A positive change from baseline in the health state score indicates that the participant's health state has improved.
Change From Baseline in the Number of Headache Days Baseline (prior to first dose of BOTOX®) to ADM last [median 20.30 months] At each visit, participants were asked to provide the number of headache days he/she experienced in the last month. A headache day was defined as 4 or more hours of continuous headache. A negative change from Baseline (less headache days) indicates improvement.
Percentage of Participants With Good or Very Good Responses on the 4-Point Treatment Satisfaction Scale ADM last [median 20.30 months] At each visit, participants and physicians were asked to indicate the level of satisfaction that he/she had with the treatment. Physicians indicated the level of satisfaction with the patient's treatment. The 4- point scale consisted of the following responses: insufficient, moderate, good and very good. The combined percentage of "good" and "very good" responses by participants and physicians are reported.
Trial Locations
- Locations (77)
Kathrin Krome
🇩🇪Bamberg, Germany
Ulrike Kirchhöfer
🇩🇪Erfurt, Germany
Hans-Dieter Zug
🇩🇪Böblingen, Germany
Astrid Gendolla
🇩🇪Essen, Germany
Veit Becker
🇩🇪Hamburg, Germany
Schmerzzentrum Rhein Main in Frankfurt
🇩🇪Frankfurt, Germany
Bernhard Hellwig
🇩🇪Freiburg, Germany
Borries Kukowski
🇩🇪Göttingen, Germany
Jürgen Hamacher
🇩🇪Essen, Germany
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany
Hodeverket Headache Clinic
🇳🇴Sandnes, Norway
Praxis für Neurologie und SchmerzMedizin
🇩🇪München, Germany
Frank Freitag
🇩🇪Potsdam, Germany
Ulrike Köhler
🇩🇪Heidelberg, Germany
Roland Leger
🇩🇪Nürnberg, Germany
Universität Rostock, Klinik für Neurologie
🇩🇪Rostock, Germany
Neuroscience Center Leipzig
🇩🇪Leipzig, Germany
Schmerztherapiezentrum Münster
🇩🇪Münster, Germany
Hospital Universitario de Burgos
🇪🇸Burgos, Spain
University Hospital of North Staffordshire, Neurology Research Unit
🇬🇧Stoke on Trent, United Kingdom
Centralsjukhuset i Karlstad
🇸🇪Karlstad, Sweden
Spire Hull and East Riding Hospital
🇬🇧Anlaby, United Kingdom
Manfred Oberling
🇩🇪Bad Camberg, Germany
Christoph Engelmann
🇩🇪Berlin, Germany
Nicole Strickling
🇩🇪Aachen, Germany
Bezirksklinikum Mainkofen
🇩🇪Deggendorf, Germany
Migräne-Klinik Königstein
🇩🇪Königstein, Germany
Dirk Buschmann
🇩🇪Herford, Germany
Schmerzklinik Kiel
🇩🇪Kiel, Germany
Dietmar Walter Noack
🇩🇪Limburgerhof, Germany
Lothar Klimpel
🇩🇪Limburgerhof, Germany
St.-Marien-Hospital GmbH
🇩🇪Lünen, Germany
Institut für Forschung und Prävention
🇩🇪Mainz, Germany
Stephan Nautscher-Timmermann
🇩🇪Mühlhausen, Germany
Dr. Becker Rhein-Sieg-Klinik
🇩🇪Nümbrecht, Germany
Ingo Palutke
🇩🇪Stadtroda, Germany
mediPlan Klinik GmbH
🇩🇪Ostfildern, Germany
Anselm Kornhuber
🇩🇪Ulm, Germany
Parkinson-Klinik Wolfach
🇩🇪Wolfach, Germany
Michaela Krause
🇩🇪Wolfratshausen, Germany
MVZ Schmerzzentrum Berlin
🇩🇪Berlin, Germany
Andreas Schwittay
🇩🇪Böhlen, Germany
Andreas Kupsch
🇩🇪Berlin, Germany
Heike Förster
🇩🇪Baunatal, Germany
Michael Kiszka
🇩🇪Erfurt, Germany
G. Müller-Schwefe
🇩🇪Göppingen, Germany
Hanno Jaeger
🇩🇪Hamburg, Germany
Klaus Gerlach
🇩🇪Hannover, Germany
Peter Asmus
🇩🇪Geldern, Germany
Frank Halbgewachs
🇩🇪Heidenheim, Germany
Rotes Kreuz Krankenhaus Kassel
🇩🇪Kassel, Germany
Matthias Röder
🇩🇪Oberhausen, Germany
Olaf Günther
🇩🇪Magdeburg, Germany
Klinikum der Universität München - Großhadern, Neurologische Klinik
🇩🇪München, Germany
Matthias Haslbeck
🇩🇪München, Germany
Neurologie und Kopfschmerzzentrum Münchner Freiheit
🇩🇪München, Germany
Universitätsklinikum Ulm, Klinik für Neurologie
🇩🇪Ulm, Germany
Heinz Peter Herbst
🇩🇪Stuttgart, Germany
Volker Heinicke
🇩🇪Weimar, Germany
Jochen Ulzheimer
🇩🇪Würzburg, Germany
Azienda Ospedaliera Sant'Andrea
🇮🇹Roma, Italy
Dorothea Händel
🇩🇪Zwickau, Germany
Ospedale Careggi
🇮🇹Firenze, Italy
LLC Center for Interdisciplinary Dentistry and Neurology
🇷🇺Moscow, Russian Federation
LLC Neyroklinika
🇷🇺Khabarovsk, Russian Federation
Istituto Neurologico Carlo Besta di Milano
🇮🇹Milano, Italy
LLC Clinic Sesil +
🇷🇺Moscow, Russian Federation
LLC University Headache Clinic
🇷🇺Moscow, Russian Federation
Hospital Universitario Reina Sofía
🇪🇸Córdoba, Spain
LLC Sibneuromed
🇷🇺Novosibirsk, Russian Federation
Hospital Universitario Virgen de la Victoria
🇪🇸Málaga, Spain
Hospital Central de Asturias
🇪🇸Oviedo, Spain
Löfvingkliniken
🇸🇪Göteborg, Sweden
Hospital Santiago de Compostela
🇪🇸Santiago de Compostela, Spain
Hospital Galdácano
🇪🇸Usansolo, Spain
Läkarhuset Utsikten
🇸🇪Stockholm, Sweden
Mid Yorkshire NHS Trust
🇬🇧Wakefield, United Kingdom